Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Yupelri (revefenacin) is indicated for the maintenance treatment of chronic obstructive pulmonary disease (COPD).
• This summary is based on the review of two systematic review(s)/meta-analysis(es). ^[1-2]
• Revefenacin (REV) at a dose of 175 µg/day significantly improved trough FEV1 in patients with moderate to very severe COPD, with a mean difference (MD) of 143.67 mL (95% CI: 129.67 to 157.68), based on data from 809 participants across 4 studies.
• REV at 175 µg/day was found to be inferior to tiotropium regarding long-term efficacy, based on very low-quality to low-quality evidence.
• No specific differences in effectiveness among different population types or subgroups were noted in the evidence provided.
• There were no significant differences in the risk of discontinuation due to adverse events, all-grade adverse events (AEs), or serious adverse events (SAEs) between COPD patients receiving 175 µg revefenacin and those receiving a placebo. The most frequently reported adverse event in both groups was COPD worsening/exacerbation. The risk of antimuscarinic-related AEs, cardiovascular AEs, or 12 commonly reported AEs did not significantly increase with 175 µg revefenacin. Meta-analyses showed no increased risk of AEs (OR=0.98, 95% CI: 0.81 to 1.18) or SAEs (OR=0.89, 95% CI: 0.55 to 1.46).
• The safety profile of 175 µg/day revefenacin was comparable to that of tiotropium and ipratropium, with no superior safety advantage observed.